Document is current
Any future updates will be listed below
-
Authors
Averbuch, Itamar
Edri, Nofar
Asher, Nethanel
Markel, Gal
Hendler, Daniel
Ditzian Kugler, Hadas
Yosefof, Eyal
Kurman, Noga
- License Information
-
More Information
Article History
Received: 6 March 2025
Accepted: 12 June 2025
First Online: 5 July 2025
Declarations
:
: Gal Markel reports receiving personal fees from MSD and Roche; grants and personal fees from BMS and Novartis; personal fees and stock options from 4C Biomed; and stock options from Nucleai, Biond Biologics, and Ella Therapeutics, outside the submitted work. Nethanel Asher reports receiving honoraria for professional services, including speaking engagements, lectures, or advisory board roles from MSD, Medison, and Taro. Additionally, Nethanel Asher is involved in an advisory board and steering committee for EUMelaReg. Itamar Averbuch, Nofar Edri, Daniel Hendler, Hadas Ditzian Kugler, Eyal Yosefof and Noga Kurman report no conflict of interest.
